Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00949819 · ClinicalTrials.gov registry record
Active Surveillance for Cancer of the Prostate (ASCaP)
A clinical trial of Prostate Cancer, sponsored by Jonsson Comprehensive Cancer Center.
- Recruiting
- Registry status
- 462
- Enrollment target
- 1
- Study location
NCT00949819: Recruiting study of Prostate Cancer, sponsored by Jonsson Comprehensive Cancer Center.
NCT00949819 is a study of Prostate Cancer that is actively recruiting participants, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 462 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (24% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00949819, a study of Prostate Cancer, is actively recruiting participants, sponsored by Jonsson Comprehensive Cancer Center.
- RECRUITING
- Registry status
- 462 participants
- Enrollment target
- 1
- Study location
Study Summary
Active Surveillance (A.S.) of prostate cancer (CaP) is the systematic monitoring of men with low-risk, localized lesions, with curative treatment of those whose tumors show substantial progression. A.S. is different from Watchful Waiting (W.W.), which is the palliative treatment of men with progressive prostate cancer.
Conditions Studied
Interventions
- OTHER Active surveillance
Study Locations (1)
California
- University of California Los Angeles - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 462 participants |
| Start Date | 2009-07-04 |
| Est. Completion | 2028-12 |
What NCT00949819 shows while recruiting
NCT00949819 is an observational study that tracks outcomes without assigning an intervention. The registered 462 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (24% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Active surveillance is the first listed.
NCT00949819 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00949819 about?
NCT00949819 is a clinical study titled "Active Surveillance for Cancer of the Prostate (ASCaP)". Active Surveillance (A.S.) of prostate cancer (CaP) is the systematic monitoring of men with low-risk, localized lesions, with curative treatment of those whose tumors show substantial progression. A.S. is different from Watchful Waiting (W.W.), which is the palliative treatment of men with progress...
What is the current status of trial NCT00949819?
This trial is currently recruiting. The enrollment target is 462 participants. The study started on 2009-07-04. Estimated completion is 2028-12.
What conditions does trial NCT00949819 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00949819?
The interventions under investigation include: Active surveillance (OTHER).
Who is sponsoring clinical trial NCT00949819?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00949819 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00949819's enrollment target sits among peer trials
462 122nd of 735 higher than 614 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05126277 · 462 participants · Phase 3
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
- NCT04546399 · 461 participants · Phase 2
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT04855656 · 464 participants · Phase 1
Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
- NCT06283927 · 464 participants
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI